| Elizabeth Nega, MD | |
|
101 W 8th Ave, Spokane, WA 99204-2307 | |
| (509) 459-9010 | |
| Not Available |
| Full Name | Elizabeth Nega |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 33 Years |
| Location | 101 W 8th Ave, Spokane, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033284609 | NPI | - | NPPES |
| PENDING | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD60015348 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Prov Sacred Hrt Med Ctr & Childs Hosp. | Spokane, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of Washington | 9032022579 | 1480 |
News Archive
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention. The paper will be published May 15 in Cancer Research.
Colchicine, when given in addition to conventional therapy, was more effective than placebo in reducing the incidence of recurrence and the persistence of symptoms of pericarditis in a randomised controlled trial.
In some patients who died with severe COVID-19 and respiratory failure, a jelly was formed in the lungs. Researchers have now established what the active agent in the jelly is and thanks to that, this new discovery can now be the key to new effective therapies.
Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.
› Verified 6 days ago
| Entity Name | Kaiser Foundation Health Plan Of Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396810701 PECOS PAC ID: 9032022579 Enrollment ID: O20031112000454 |
News Archive
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention. The paper will be published May 15 in Cancer Research.
Colchicine, when given in addition to conventional therapy, was more effective than placebo in reducing the incidence of recurrence and the persistence of symptoms of pericarditis in a randomised controlled trial.
In some patients who died with severe COVID-19 and respiratory failure, a jelly was formed in the lungs. Researchers have now established what the active agent in the jelly is and thanks to that, this new discovery can now be the key to new effective therapies.
Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Nega, MD 101 W 8th Ave, Spokane, WA 99204-2307 Ph: (509) 459-9010 | Elizabeth Nega, MD 101 W 8th Ave, Spokane, WA 99204-2307 Ph: (509) 459-9010 |
News Archive
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention. The paper will be published May 15 in Cancer Research.
Colchicine, when given in addition to conventional therapy, was more effective than placebo in reducing the incidence of recurrence and the persistence of symptoms of pericarditis in a randomised controlled trial.
In some patients who died with severe COVID-19 and respiratory failure, a jelly was formed in the lungs. Researchers have now established what the active agent in the jelly is and thanks to that, this new discovery can now be the key to new effective therapies.
Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.
› Verified 6 days ago
Ms. Deirdre Marie Mooney, MD, MPH Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 122 W 7th Ave Ste 450, Spokane, WA 99204 Phone: 509-455-8820 | |
Dr. Rebecca Raluca Teona Muntean, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 820 S Mcclellan St, Suite 200, Spokane, WA 99204 Phone: 509-747-1144 Fax: 509-455-4166 | |
Dr. Arnold L Klipstein, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 801 W 5th Ave Ste 309, Spokane, WA 99204 Phone: 509-838-2531 Fax: 509-755-6580 | |
Dr. Joseph W Davis, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 104 W 5th Ave Ste 200w, Spokane, WA 99204 Phone: 509-744-3750 Fax: 509-744-3969 | |
John G Peterson, MD, FACC Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 212 E Central Ave, Suite 240, Spokane, WA 99208 Phone: 509-455-8820 Fax: 509-838-4978 | |
Elizabeth C Ho, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 546 N Jefferson Ln Ste 200, Spokane, WA 99201 Phone: 509-625-3700 Fax: 509-625-3747 | |
Michael F. Kestell, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 105 W 8th Ave, Suite 6010, Spokane, WA 99204 Phone: 509-838-5950 Fax: 509-838-5961 |